|Systematic (IUPAC) name|
Nitromethaqualone is an analogue of methaqualone that has similar sedative and hypnotic properties. It is significantly more potent (10x) compared to the parent compound; the typical dose is approximately 25 mg. However, the aromatic nitro group is metabolised to the corresponding aniline, which proved to be a mutagen. As a consequence, nitromethaqualone was not developed further due to toxicity concerns.
- US patent 3162634, Klosa, J. (Berlin, Germany), "2-Methyl-3-(2'-methyl-3'-chlorphenyl)-quinazolone-(4)", issued 1964-12-22
- Szirmai, A. (1963). "(title in German)" [Pharmacological and Therapeutic Studies with a New Quinazolone Derivative, Nitromethaqualone]. Therapeutische Umschau (in German) 20: 542–546.
- van Boven, M.; Daenens, P. (1982). "Biotransformation and Excretion of Nitromethaqualone in Rats and Humans". Journal of Pharmaceutical Sciences 71 (10): 1152–1157.